CSI Market
Sign In | Register

Edwards Lifesciences (EW) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access EW Annual Cash Flow →
This page allows investors to follow Edwards Lifesciences's cash flow patterns across multiple reporting periods and assess consistency in cash generation.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income622.10
Depreciation & amortization83.60
Amortization of Other Assets0.00
Other non-cash charges0.00
Asset Impairment Charges163.60
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories25.10
Minority interests0.00
Gain (Loss) on Disposition of Business0.00
Share-based Compensation87.60
Income from affiliates0.00
Tax benefit on stock options0.00
Operating Lease Right Of Use Asset Amortization-
Impairment Of Investments-
Operating Lease Right Of Use Asset Amortization Expense6.50
Business Combination Step Acquisition Equity Interest In Acquiree Remeasurement Gain Or Loss-65.20
Increase Decrease In Legal Settlement Accrual-50.00
Income taxes0.00
Gain (Loss) on Investments0.00
Increase (Decrease) in Accounts and Other Receivables128.10
Increase (Decrease) in Accounts Payable and Accrued Liabilities-223.40
Accrued liabilities0.00
Deferred revenue0.00
Prepaid Expense and Other Assets-211.50
Other Working Capital17.70
Other Noncash Income (Expense)10.30
Other net-0.50
Payments for (Proceeds from) Other Operating Activities-7.00
Discontinued operations0.00
Net Cash flow from Operating Activities695.70
Investing Activities
Capital Expenditures-131.80
Sale of Capital Items0.00
Short-term Investments Proceeds1,171.10
Short-term Investments Acq.-1,217.70
Proceeds from other investments0.00
Payments To Acquire Proceeds From Sale Of Trading Securities Heldforinvestment-
Payments For Proceeds From Interest In Subsidiaries And Affiliates-
Payments For Proceeds From Trading Securities Investments-
Proceeds from Paymentsto Trading Securities Heldforinvestment-
Disposal Group Payment For Working Capital Adjustment-
Purchases of other investments0.00
Noncontrolling interest0.00
Proceeds from Investments0.00
Payments for (Proceeds from) Other Investments0.00
Purchases of non-current assets0.00
Other Payments to Acquire Businesses0.00
Payments to Acquire Interest in Subsidiaries and Affiliates-13.40
Proceeds from Divestiture of Businesses0.00
Proceeds from sale of assets0.00
Payments to Acquire Receivables-53.20
Payments for (Proceeds from) Other Investing Activities-7.30
Other Net-33.70
Discontinued operations0.00
Net Cash Flow from Investing Activities-286.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Noncontrolling interest0.00
Issuances / -repurchases of Comm. Stock-452.40
Exercise of stock options0.00
Issuances / -repurchases of Pref. Stock0.00
Discontinued Operations0.00
Other financing activities net0.90
Other net0.00
Payments Related To Equity Forward Contract In Accelerated Share Repurchase Agreement-
Payments For Equity Forward Contract Related To Accelerated Share Repurchase Agreement-100.00
Dividends paid to minority interests0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-451.50
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow563.90
Total Cash Flow-29.80
4 historic quarters locked

Sign in to unlock the full Edwards Lifesciences cash flow history.

Sign In Create Free Account

About Edwards Lifesciences Corp Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20260630)
  • Filed with the SEC: August 4, 2026
  • Source: ew-20260630.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001099800-26-000043

Figures are derived from filed reports and may be restated. Historical data is subject to revision.